Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.58 |
| ▸ | RAMP3 | O60896 | 7/20 | 0.52 |
| ▸ | CALCR | P30988 | 7/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 8/20 | 0.51 |
| ▸ | NTSR2 | O95665 | 7/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 6/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31344445 | 0.89 | KEAP1 (0.51) | MAPK8MAPK9MAPK10RAMP3CALCR | |
| SCHEMBL31307290 | 0.89 | EP300 (0.53) | MAPK8MAPK9MAPK10RAMP3CALCR | |
| SCHEMBL30974082 | 0.89 | RAMP3 (0.55) | MAPK8MAPK9MAPK10RAMP3CALCR | |
| SCHEMBL30338867 | 0.88 | MAPK8 (0.53) | MAPK8MAPK9MAPK10RAMP3CALCR | |
| SCHEMBL31031621 | 0.88 | NPY2R (0.58) | MAPK8MAPK9MAPK10RAMP3CALCR | |
| SCHEMBL31461868 | 0.88 | NTSR2 (0.51) | MAPK8MAPK9MAPK10RAMP3CALCR | |
| SCHEMBL31462079 | 0.87 | MAPK8 (0.53) | MAPK8MAPK9MAPK10RAMP3CALCR | |
| SCHEMBL29914215 | 0.87 | MAPK8 (0.52) | MAPK8MAPK9MAPK10RAMP3CALCR | |
| SCHEMBL30512672 | 0.86 | MAPK8 (0.53) | MAPK8MAPK9MAPK10NTSR1NTSR2 | |
| SCHEMBL29651846 | 0.86 | KEAP1 (0.53) | MAPK8MAPK9MAPK10RAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692332-A1 | PRODUCTION METHOD FOR MEGAKARYOCYTES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-02-11 | — | — | EP | disclosed |
| EP-4644539-A1 | METHOD FOR REGULATING DEGREE OF CELL DIFFERENTIATION | National University Corporation Chiba University (JP) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025098488-A1 | DRUG UPREGULATING P53 PROTEIN EXPRESSION OR ACTIVATING P53 FUNCTION AND DNA ALKYLATING AGENT USED IN COMBINATION FOR TREATING CANCER | 深圳艾欣达伟医药科技有限公司 | 2025-05-15 | — | — | WO | disclosed |
| WO-2025099460-A1 | CALIBRATOR | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-05-15 | — | — | WO | disclosed |
| US-20250057813-A1 | APOPTOSIS RELATED PROTEIN IN THE TGF-BETA SIGNALING PATHWAY (ARTS) MIMETIC COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF IN INDUCTION OF APOPTOSIS | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2025-02-20 | — | — | US | disclosed |
| WO-2024210126-A1 | PRODUCTION METHOD FOR MEGAKARYOCYTES | 大塚製薬株式会社 | 2024-10-10 | — | — | WO | disclosed |
| US-20240301353-A1 | METHOD FOR IMPROVING PROLIFERATIVE PROPERTIES OF COMMON MYELOID PROGENITOR CELLS (CMP) OR MYELOCYTIC PROGENITOR CELLS | NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (JP) | 2024-09-12 | — | — | US | disclosed |
| WO-2024143555-A1 | METHOD FOR REGULATING DEGREE OF CELL DIFFERENTIATION | 国立大学法人千葉大学 | 2024-07-04 | — | — | WO | disclosed |
| EP-4365283-A1 | METHOD FOR IMPROVING PROLIFERATIVE PROPERTIES OF COMMON MYELOID PROGENITOR CELLS (CMP) OR MYELOCYTIC PROGENITOR CELLS | National University Corporation Chiba University (JP) | 2024-05-08 | — | — | EP | disclosed |
| US-20240110230-A1 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| CN-117801060-A | Antitumor polypeptide and application thereof | 深圳碳云智肽药物科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4291902-A2 | BIOMARKERS FOR CANCER TREATMENT | Foundation Medicine, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023166507-A1 | APOPTOSIS RELATED PROTEIN IN THE TGF-BETA SIGNALING PATHWAY (ARTS) AND ARTS MIMETIC SMALL MOLECULE COMPOUNDS FOR UPREGULATING P53 LEVEL | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023093303-A1 | P53-TARGETED POLYPEPTIDE AND USE THEREOF IN PREPARATION OF DRUG FOR TREATING CANCER | 深圳碳云智肽药物科技有限公司 | 2023-06-01 | — | — | WO | disclosed |
| CN-116178501-A | P53 targeting polypeptide and application thereof in preparation of medicines for treating cancers | 深圳碳云智肽药物科技有限公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2023277153-A1 | METHOD FOR IMPROVING PROLIFERATIVE PROPERTIES OF COMMON MYELOID PROGENITOR CELLS (CMP) OR MYELOCYTIC PROGENITOR CELLS | 国立大学法人千葉大学 | 2023-01-05 | — | — | WO | disclosed |
| WO-2022174234-A2 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057813-A1 | APOPTOSIS RELATED PROTEIN IN THE TGF-BETA SIGNALING PATHWAY (ARTS) MIMETIC COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF IN INDUCTION OF APOPTOSIS | BID, BIRC5, BAD | MAPK8 993/4885MAPK9 796/4885MAPK10 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.